Kerri Fitzgerald

DocwireNews

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms (MPNs), is associated with worsening <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/cardiac-synchronization-therapy-helps-cancer-survivors-with-heart-failure/">cardiometabolic health</a>, according to an article published in Scientific Reports.The retrospective study analyzed data from 69 adults (mean age, 65 years) with MPNs who initiated ruxolitinib between 2010 and 2017 at Mount Sinai and were identified from electronic medical records.<h2>Increased cardiometabolic concerns</h2>Patients&rsquo; body weight increased from a mean of 73.9 kg at baseline to 78.54 kg at 72 weeks (P&lt;0.001), with 50% of patients gaining more than 5% of their baseline body weight. Body mass index increased from 25.8 kg/m&sup2; at baseline to 27.5 kg/m&sup2; at 72 weeks (P&lt;0.001).Adults treated with ruxolitinib had a <a href="https://www.docwirenews.com/home-page-editor-picks/obesity-prevalent-among-hypertrophic-cardiomyopathy-patients/">higher systolic blood pressure</a> (P=0.03), as well as serum aspartate aminotransferase (P=0.01) and alanine aminotransferase&nbsp;(P=0.04) at 72 weeks.&ldquo;As pharmacological JAK1/2 inhibitors are being developed and used in clinical practice, it is important to understand their long-term metabolic consequences,&rdquo; the researchers concluded.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Ruxolitinib for Myeloproliferative Neoplasms Worsens Cardiometabolic Health

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms (MPNs), is associated with worsening ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe